Nagato T, Kobayashi H, Kishibe K, et al. Expression of Interleukin-9 in Nasal Natural Killer/T-Cell Lymphoma Cell Lines and Patients[J]. Clin Cancer Res, 2005, 11(23): 8250-8257.
[2]
Quermalet VR, Giustiniani J, Cardine AM, et al. Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas[J]. Oncogene, 2006, 25(19): 2807-2811.
Kim J, Kim EY, Lee SK, et al. Extranodal nasal-type NK/T-cell lymphoma: computed tomography findings of head and neck involvement[J]. Acta Radiol, 2010, 51(2): 164-169.
[5]
Ou CH, Chen CCC, Ling JC, et al. Nasal NK/T-cell lymphoma: computed tomography and magnetic resonance imaging findings[J]. J Chin Med Assoc, 2007, 70(5): 207-212.
[6]
Karantanis D, Subramaniam RM, Peller PJ, et al. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma[J]. Clin Lymphoma Myeloma, 2008,8(2): 94-99.
[7]
Kako1 S, Izutsu1 K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms[J]. Ann Oncol, 2007, 18(10): 1685-1690.
[8]
Chan WKS, Au WY, Wong CYO, et al. Metabolic activity measured by 18F FDG PET in natural killer-cell lymphoma compared to aggressive B-and T-cell lymphomas[J]. Clin Nuclear Med, 2010, 35(8): 571-575.
[9]
Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma[J]. Am Cancer Societ, 2007, 110(3): 652-659.
[ 1 ] Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006[J]. Pathol Int, 2008, 58(3): 174-182.
[12]
[ 2 ] Ko YH, Kim CW, Park CS, et al. REAL classication of malignant lymphomas in the republic of Korea[J]. Cancer, 2008, 83(4): 806-812.
[ 6 ] Assaf C, Gellrich S, Whittaker S, et al. CD 56-positive haematological neoplasms of the skin: a multicentre study of the cutaneous lymphoma project group of the European organisation for research and treatment of cancer[J]. Clin Pathol, 2007, 60(9): 981-989.
[17]
[ 7 ] Mitarnun W, Suwiwat S, Pradutkanchana J. Epstein-Barr virus-associated extranodal non-Hodgkin’s lymphoma of the sinonasal tract and nasopharynxin Thailand[J]. Asian Pac J Cancer Prev, 2006, 7(1): 91-94.
[18]
[ 8 ] Liu A, Nakatsuka S, Yang WI, et al. Expression of cell adhesion molecules and chemokine receptors: angioinvasiveness in nasal NK/T cell lymphoma[J]. Oncol Rep, 2005, 13(4): 613-620.
[19]
[ 9 ] Kuo TT, Shih LY, Tsang NM. Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities[J]. Int J Surg Pathol, 2004, 12(4): 375-387 .
[20]
Ramakrishnan R, Donahue H, Garcia1 D, et al. Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas[J]. PLoS ONE, 2011, 6(11): e27271.
[21]
Asada H, Saito-Katsuragi M, Niizeki H. Mosquito salivary gland extracts induce EBV-infected NK cell oncogenesis via CD4+ T cells in patients with hypersensitivity to mosquito bites[J]. J Invest Dermatol, 2005, 125(5): 956-961.
[22]
Chiu BCH, Dave BJ, Blair A, et al. Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma[J]. Blood, 2006, 108(4): 1363-1369.
[23]
Aozasa K, Takakuwa T, Hongyo T, et al. Nasal NK/T-cell lymphoma: epidemiology and pathogenesis [J]. Int J Hematol, 2008, 87(2): 110-117.
[24]
Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T-cell lymphoma revealed by gene expression profiling[J]. J Pathol, 2010, 223(4): 496-510.
[25]
Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials[J]. Blood, 2007, 109(5): 2183-2189.
[26]
HuangY, Reynies A, Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways in extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2010, 115(6): 1226-1237.
Pongpruttipan T, Kummalue T, Bedavanija A, et al. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand[J]. Diagn Pathol, 2011, 6(1): 79-90.
Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring[J]. Blood, 2008, 112(8): 3057-3064.
[31]
Li YX, Liu QF, Fang H, et al. Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma[J]. Clin Cancer Res, 2009, 15(8): 2905-2912.
[32]
Kitazawa Y, Saito F, Nomura S, et al. A case of hemophagocytic lymphohistiocytosis after the primary Epstein-Barr virus infection[J]. Clin Appl Thromb Hemost, 2007, 13(3): 323-328.
[33]
Imashuku S, Kuriyama K, Sakai R, et al. Treatment of Epstein-Barr virus associated hemophagocytic lymphohistiocytosis ( EBV-HLH) in young adults: a report from the HLH study center[J]. Med Pediatr Oncol, 2003, 41(2): 103-109.
Kwong YL, Anderson BO, Adwani R, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009[J]. Lancet Oncol, 2009, 10(11): 1093-1101.
[37]
Ishii H, Ogino T, Berger C, et al. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for nasal NK/T-cell lymphoma[J]. J Med Virol, 2007, 79(5): 562-572.
[38]
Harabuchi Y, Takahara M, Kishibe K, et al. Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological and genetic features[J]. Int J Clin Oncol, 2009, 14(3): 181-190.
